daznelimgene lisbac
AssetAlso Herlystic, OST-HER2
Listeria-based immunotherapy targeting HER2-expressing cancer cells.
- Stage
- Phase 2
- Modality
- Vaccine
- Target
- ERBB2
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Pulmonary metastatic osteosarcoma
Phase 2, newsfilecorp.com, 6 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.